Skip to main content
. 2010 Jun 30;2010:321950. doi: 10.1155/2010/321950

Figure 2.

Figure 2

IgG reactivity against desmoglein 3 (Dsg3) subdomains in pemphigus vulgaris (PV) patients on rituximab (Rtx). Illustrated is the number of PV patients showing IgG against Dsg3 subdomains before and 6 and 12 months after treatment with Rtx, respectively.